Global Lumpectomy Therapy Market Size By Type (Lumpectomy Systems, Lumpectomy Surgical Tools), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Lumpectomy Therapy Market was valued at USD 2.3 billion in 2023 and is projected to reach USD 4.1 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. Lumpectomy, often referred to as breast-conserving surgery, is gaining widespread adoption due to its minimally invasive nature and effectiveness in early-stage breast cancer treatment. Increasing awareness of breast cancer screening, advancements in surgical techniques, and rising demand for cosmetic outcomes post-surgery are driving the global lumpectomy therapy market forward.

Drivers

1. Rising Incidence of Breast Cancer:

A significant driver is the global increase in breast cancer prevalence, especially among women over 40. Early diagnosis through screening programs has led to a surge in demand for conservative surgical options like lumpectomy.

2. Preference for Minimally Invasive Procedures:

Patients and healthcare providers are increasingly opting for lumpectomy over mastectomy due to lower physical trauma, preservation of breast appearance, and quicker recovery time.

3. Technological Advancements:

Innovations in imaging guidance, margin assessment tools, and oncoplastic techniques have enhanced the precision and outcomes of lumpectomy procedures, boosting market adoption.

Restraints

1. Risk of Recurrence and Reoperations:

Despite its advantages, lumpectomy poses risks of local recurrence and may require additional surgeries, which can deter some patients and clinicians from choosing it.

2. Limited Accessibility in Low-Income Regions:

Lack of adequate screening and surgical infrastructure in developing countries remains a significant barrier to lumpectomy therapy adoption.

Opportunity

1. Expansion in Emerging Markets:

Healthcare infrastructure improvements in Asia-Pacific, Latin America, and Africa are creating opportunities for broader adoption of lumpectomy therapy, especially with international support for breast cancer awareness.

2. Integration of AI and Imaging in Surgical Planning:

The integration of artificial intelligence and 3D imaging into pre-surgical planning is anticipated to reduce recurrence risks and improve surgical outcomes, opening new avenues for market growth.

Market by System Type Insights

Based on system type, the Image-Guided Lumpectomy Systems segment dominated the market in 2023. These systems provide surgeons with precise tumor localization, improving margin clearance rates and reducing the need for reoperations. The adoption of intraoperative imaging and smart biopsy devices is expected to drive this segment further.

Market by End-use Insights

In 2023, the Hospitals & Specialty Clinics segment accounted for the largest market share. These facilities offer comprehensive cancer care and have access to advanced surgical infrastructure and oncology expertise. The growing focus on personalized cancer care and increasing patient inflow make this segment a major revenue contributor.

Market by Regional Insights

North America led the lumpectomy therapy market in 2023, driven by strong healthcare systems, early diagnosis practices, and favorable reimbursement policies. However, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period, propelled by government-led breast cancer awareness initiatives, improving medical infrastructure, and a rising patient population.

Competitive Scenario

Key players in the Global Lumpectomy Therapy Market include:

Hologic, Inc.

Becton, Dickinson and Company

Carl Zeiss Meditec AG

Cianna Medical (part of Merit Medical Systems)

Seno Medical Instruments

Medtronic plc

Endomag

IceCure Medical

Theraclion

iCAD, Inc.

These companies are focused on advancing lumpectomy-related technologies, entering strategic partnerships, and expanding into high-growth markets. For example:

In 2023, Endomag launched an upgraded version of its magnetic seed localization system for better surgical precision.

In 2024, Hologic acquired a leading AI company specializing in breast imaging to enhance its lumpectomy workflow solutions.

In 2025, IceCure Medical announced FDA approval of its cryoablation technology as an adjunct to lumpectomy for early-stage tumors.

Scope of Work – Global Lumpectomy Therapy Market

Key Market Developments

July 2023: Hologic expanded its partnership with software providers to integrate AI-based tumor localization systems.

March 2024: iCAD Inc. introduced real-time margin assessment technology to reduce reoperation rates.

February 2025: Seno Medical Instruments received CE Mark for its opto-acoustic imaging device designed to assist in lumpectomy planning.

FAQs

1) What is the current market size of the Global Lumpectomy Therapy Market?

The market was valued at USD 2.3 billion in 2023.

2) What is the major growth driver of the Global Lumpectomy Therapy Market?

The major growth driver is the rising incidence of breast cancer and increasing preference for minimally invasive treatments.

3) Which is the largest region during the forecast period in the Global Lumpectomy Therapy Market?

North America is the largest region, supported by advanced diagnostic infrastructure and strong awareness programs.

4) Which segment accounted for the largest market share in the Global Lumpectomy Therapy Market?

The Hospitals & Specialty Clinics segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Lumpectomy Therapy Market?

Key players include Hologic, Inc., Becton, Dickinson and Company, Carl Zeiss Meditec AG, Endomag, and IceCure Medical.